Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Daisuke TomizawaHiroyuki Ishida

Abstract

Few reports have focused on adolescent and young adult (AYA) patients with acute myeloid leukemia (AML) treated with hematopoietic stem cell transplantation (HSCT). We performed a retrospective analysis based on data obtained from a Japanese nationwide registration database to compare HSCT outcomes in AYA patients with AML with those in children with AML. An analysis of the 2973 patients with de novo AML who received allogeneic HSCT from 1990 to 2013 showed inferior 5-year overall survival (OS) (54% versus 58%, P <.01) and increased treatment-related mortality (TRM) (16% versus 13%, P = .02) in AYA patients. Multivariate analysis for both OS and TRM showed a significant negative impact on AYAs. However, the negative impact of older age lost its significance in an additional analysis focusing on 1407 recent transplant recipients with high-resolution HLA typing (2000 to 2013). Finally, we analyzed the impact of transplantation center type on HSCT outcomes in 317 adolescent patients (15 to 18 years old) and found no difference in outcomes between patients treated at a pediatric or an adult hospital. Higher age was a strong predictive factor for inferior OS resulting from increased TRM, which can be eliminated with better donor sel...Continue Reading

Citations

Oct 14, 2017·International Journal of Hematology·Yachiyo KuwatsukaHitoshi Kiyoi
Oct 1, 2020·Pediatric Transplantation·Brian Norman DangTheodore Bruce Moore
Apr 19, 2018·Pediatric Blood & Cancer·Ursula CreutzigRaul C Ribeiro
Jan 12, 2021·Cancer Science·Kayo NakataUNKNOWN Osaka Cancer Association for Children, Adolescents, Young Adults
Mar 9, 2021·Frontiers in Oncology·Zhiheng ChengTiansheng Zeng
Apr 11, 2021·Transplantation and Cellular Therapy·Shohei MizunoMasamitsu Yanada
Jan 10, 2019·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hemalatha G RangarajanSarah H O'Brien

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
J D PoleL Sung
Annals of Hematology
Takaaki KonumaAdult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Navneet S MajhailBrandon M Hayes-Lattin
© 2022 Meta ULC. All rights reserved